Literature DB >> 16959872

A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway.

Roberta Avallone1, Annie Demers, Amélie Rodrigue-Way, Kim Bujold, Diala Harb, Silvia Anghel, Walter Wahli, Sylvie Marleau, Huy Ong, André Tremblay.   

Abstract

Macrophages play a central role in the pathogenesis of atherosclerosis by accumulating cholesterol through increased uptake of oxidized low-density lipoproteins by scavenger receptor CD36, leading to foam cell formation. Here we demonstrate the ability of hexarelin, a GH-releasing peptide, to enhance the expression of ATP-binding cassette A1 and G1 transporters and cholesterol efflux in macrophages. These effects were associated with a transcriptional activation of nuclear receptor peroxisome proliferator-activated receptor (PPAR)gamma in response to binding of hexarelin to CD36 and GH secretagogue-receptor 1a, the receptor for ghrelin. The hormone binding domain was not required to mediate PPARgamma activation by hexarelin, and phosphorylation of PPARgamma was increased in THP-1 macrophages treated with hexarelin, suggesting that the response to hexarelin may involve PPARgamma activation function-1 activity. However, the activation of PPARgamma by hexarelin did not lead to an increase in CD36 expression, as opposed to liver X receptor (LXR)alpha, suggesting a differential regulation of PPARgamma-targeted genes in response to hexarelin. Chromatin immunoprecipitation assays showed that, in contrast to a PPARgamma agonist, the occupancy of the CD36 promoter by PPARgamma was not increased in THP-1 macrophages treated with hexarelin, whereas the LXRalpha promoter was strongly occupied by PPARgamma in the same conditions. Treatment of apolipoprotein E-null mice maintained on a lipid-rich diet with hexarelin resulted in a significant reduction in atherosclerotic lesions, concomitant with an enhanced expression of PPARgamma and LXRalpha target genes in peritoneal macrophages. The response was strongly impaired in PPARgamma(+/-) macrophages, indicating that PPARgamma was required to mediate the effect of hexarelin. These findings provide a novel mechanism by which the beneficial regulation of PPARgamma and cholesterol metabolism in macrophages could be regulated by CD36 and ghrelin receptor downstream effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959872     DOI: 10.1210/me.2006-0146

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  16 in total

Review 1.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

2.  A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR.

Authors:  Stéphanie Bilodeau; Véronique Caron; Jonathan Gagnon; Alexandre Kuftedjian; André Tremblay
Journal:  J Mol Cell Biol       Date:  2017-06-01       Impact factor: 6.216

3.  Salvianolic acid B inhibits macrophage uptake of modified low density lipoprotein (mLDL) in a scavenger receptor CD36-dependent manner.

Authors:  Yi Bao; Li Wang; Yanni Xu; Yuan Yang; Lifei Wang; Shuyi Si; Sunghee Cho; Bin Hong
Journal:  Atherosclerosis       Date:  2012-05-15       Impact factor: 5.162

4.  A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages.

Authors:  Annie Demers; Véronique Caron; Amélie Rodrigue-Way; Walter Wahli; Huy Ong; André Tremblay
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

5.  Feeding behavior during long-term hexarelin administration in young and old rats.

Authors:  E Bresciani; N Pitsikas; L Tamiazzo; M Luoni; I Bulgarelli; D Cocchi; V Locatelli; A Torsello
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

6.  Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis.

Authors:  Jane S Titterington; Sergiy Sukhanov; Yusuke Higashi; Charlotte Vaughn; Cyril Bowers; Patrice Delafontaine
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

7.  Identification of estrogen receptor β as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3β.

Authors:  Nathalie Picard; Véronique Caron; Stéphanie Bilodeau; Mélanie Sanchez; Xavier Mascle; Muriel Aubry; André Tremblay
Journal:  Mol Cell Biol       Date:  2012-05-14       Impact factor: 4.272

Review 8.  The Impact of Ghrelin in Metabolic Diseases: An Immune Perspective.

Authors:  Jéssica Aparecida da Silva Pereira; Felipe Corrêa da Silva; Pedro Manoel Mendes de Moraes-Vieira
Journal:  J Diabetes Res       Date:  2017-09-07       Impact factor: 4.011

9.  Fetal Cardiac Lipid Sensing Triggers an Early and Sex-related Metabolic Energy Switch in Intrauterine Growth Restriction.

Authors:  Loïze Maréchal; Benoit Sicotte; Véronique Caron; Michèle Brochu; André Tremblay
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

10.  Hexarelin Signaling to PPARgamma in Metabolic Diseases.

Authors:  Annie Demers; Amélie Rodrigue-Way; André Tremblay
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.